SAN FRANCISCO--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced data from two separate cohort evaluations, in which long-term treatment with BARACLUDE® (entecavir) was associated with improved liver histology, including improvement in fibrosis, in chronic hepatitis B patients. The histology data were presented today at the 59th Annual Meeting of the American Association for the Study of Liver Diseases.
